1. Market Research
  2. > Healthcare Market Trends
  3. > A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market

The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges.
Executive Summary
•The global human plasma-derived therapeutics market, worth $xxbillion in 2015, is set to grow at a CAGR of xx% to reach $xx billion by 2021.
•Rise in the global ageing population, increased awareness about the potential of plasma-derived therapeutics, early diagnosis of diseases, and the growing popularity of plasma-derived products in the emerging economies are the key factors driving the growth.
•However, there are significant challenges in handling the strict regulations of different countries with respect to selection of donors, plasma screening process, and fractionation process.
•In 2015, CSL Behring, Baxter, Grifols, Kedrion, and Octapharma were the top xx competitors; however, companies such as Sanquin are gaining ground quickly.
•In the past, there have been significant consolidations such as the $xx billion acquisition of Talecris in 2011 by Grifols. The market is further expected to witness big industry consolidations for economies of scale and market access.
•The IVIG segment will continue to be the market driver because of the heavy R&D investment in biologics development by market leaders such as Grifols, Octapharma, and CSL Behring.
•A recent pre-clinical research study at Stanford University showed that blood plasma derived from young mice and injected into older mice rejuvenated the health and memory of the older mice. Several other studies like this one may open up new indications such as Alzheimer’s disease and other age-related diseases for the human plasma-derived therapeutics market in the coming years.

Methodology and Scope
•This research service focuses on human plasma-derived prescription drugs used for the treatment of liver and kidney diseases, burns, surgeries, cardiopulmonary bypass, hypovolemia, albumin deficiency (hypoalbuminemia), acute nephrosis, ovarian hyperstimulation syndrome, neonatal hyperbilirubinemia, acute respiratory distress syndrome (ARDS), hereditary angioedema, Von Willebrand disease (vWD), factor VII / X / XI / XIII deficiencies, haemophilia A and B, fibrinogen deficiency, hereditary anti-thrombin deficiency, surgical bleeding, chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP), rabies, tetanus, hepatitis A and B, chickenpox, primary immunodeficiency (PI), x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott–Aldrich syndrome.
•This study does not include recombinant products and bovine-plasma products. Only human plasma-derived products have been used in market segmentation, market size, and forecasting.
•A product and pipeline assessment is provided for marketed and investigational plasma-derived products. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources including disease organisation websites; public health organisation websites; company publications including annual reports, SEC filings, and press releases; government public sources; pipeline databases; and published articles in scientific journals.

Table Of Contents

A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market

Executive Summary
•Recent Market Developments
•Key MandAs and Partnership Assessment
•Companies to Watch
Methodology and Scope
Market Background
•Market Segmentation
•Market Forecasting

Competitive Landscape
•Competitive Landscape—Human Plasma-derived Therapeutics: Marketed Products
•Competitive Landscape—Human Plasma-derived Therapeutics Market: Pipeline Products
•Competitive Landscape— Count of Marketed and Pipeline Products
•Competitive Landscape—Key Clinical Trials

Marketed Product Analysis
•Marketed Products Synopsis—Albumin
•Marketed Products Synopsis—Other Haematologicals
• Marketed Products Synopsis—Coagulation factors
• Marketed Products Synopsis—Immunoglobulins
Pipeline Product Analysis
• Pipeline Analysis—Approved
• Pipeline Analysis—Phase 3
• Pipeline Analysis—Phase 2
• Pipeline Analysis—Phase 1
Product Dashboard
• Product Dashboard—ResusixTM, Entegrion, Inc.
• Product Dashboard—CINRYZE®, Shire
• Product Dashboard—BIOSTATE® (new formulation), CSL Behring
• Product Dashboard—Gammagard, Baxter
Conclusions and Recommendations

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

  • $ 9 850
  • Industry report
  • June 2016
  • by Venture Planning Group

This report provides the following data: Geographic Coverage:-          France-          Germany-          Italy-          Japan-          Spain-          ...

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

  • $ 5 650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021, to reach USD 26.07 billion by 2021 from USD 18.84 billion in 2016. Growth in this market is mainly attributed ...

U.S. Therapeutic Plasma Exchange Market by Indication, Procedures & Patients - Forecasts to 2021

U.S. Therapeutic Plasma Exchange Market by Indication, Procedures & Patients - Forecasts to 2021

  • $ 5 650
  • Industry report
  • July 2016
  • by MarketsandMarkets

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). The rising incidences ...

Download Unlimited Documents from Trusted Public Sources

Blood Supply Industry in Europe

  • October 2016
    15 pages
  • Blood Supply  

  • Europe  

View report >

Healthcare Industry in Canada

  • October 2016
    20 pages
  • Healthcare  


  • Canada  

View report >

General Medicine And Specialty Medicine Industry in Malaysia

  • October 2016
    41 pages
  • General Medicin...  

    Emergency Medic...  

  • Malaysia  

View report >

Hospital Industry

22 days ago

Hospital Industry

22 days ago

Related Market Segments :

Blood Supply


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.